Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 1;37(2):129-136.
doi: 10.1097/QCO.0000000000001000. Epub 2024 Jan 10.

The disease burden of respiratory syncytial virus in older adults

Sebastien Kenmoe  1 , Harish Nair  1   2   3
Affiliations
Review

The disease burden of respiratory syncytial virus in older adults

Sebastien Kenmoe et al. Curr Opin Infect Dis. .

Abstract

Purpose of review: To highlight the respiratory syncytial virus (RSV) disease burden and the current developments and challenges in RSV prevention for older adults ≥60 years through analysis of RSV epidemiology and the effectiveness of emerging vaccines.

Recent findings: In industrialized countries, RSV incidence rates and hospitalization rates among older adults are estimated to be 600.7 cases per 100 000 person-years and 157 hospitalizations per 100 000 person-years, respectively. Yet, accurately determining RSV morbidity and mortality in older adults is challenging, thus resulting in substantially under-estimating the disease burden. The in-hospital fatality rates vary substantially with age and geographies, and can be as high as 9.1% in developing countries. Two promising RSV vaccines for the elderly have been approved, demonstrating efficacies of up to 94.1%, signifying considerable advancement in RSV prevention. However, concerns over potential side effects remain.

Summary: RSV is associated with a significant burden in older adults. While the landscape of RSV prevention in older adults is promising with the licensure of vaccines from two companies, current trial data underscore the need for additional studies. Addressing the real-world effectiveness of these vaccines, understanding potential rare side effects, and ensuring broad inclusivity in future trials are crucial steps to maximize their potential benefits.

PubMed Disclaimer

Conflict of interest statement

H.N. reports grants outside the submitted work from the Innovative Medicines Initiative, WHO, the National Institute for Health Research, Pfizer and Icosavax; and personal fees from the Bill & Melinda Gates Foundation, Pfizer, GSK, Merck, Abbvie, Janssen, Icosavax, Sanofi, Novavax, outside the submitted work.

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

References

    1. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg 1957; 66:281–290. - PubMed
    1. Smith EC, Popa A, Chang A, et al. . Viral entry mechanisms: the increasing diversity of paramyxovirus entry. FEBS J 2009; 276:7217–7227. - PMC - PubMed
    1. Falsey AR, Walsh EE. Respiratory syncytial virus prefusion F vaccine. Cell 2023; 186:3137–13137. e1. - PubMed
    1. CDC. RSV transmission 2023 [updated 2023/09/25]. Available at: https://www.cdc.gov/rsv/about/transmission.html.
    1. Li Y, Reeves RM, Wang X, et al. . Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Global Health 2019; 7:e1031–e1045. - PubMed